首页> Research square> Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

导出 LinkOut

翻译打印收藏纠错

第一作者： Frank,Mulindwa

第一单位： Makerere University Infectious Diseases Institute.

作者： Frank,Mulindwa ^[1] ; Barbara,Castelnuovo ^[1] ; Nele,Brusselaers ^[2] ; Martin,Nabwana ^[3] ; Robert,Bollinger ^[4] ; Eva,Laker ^[1] ; Ronald,Kiguba ^[5] ; Jean-Marc,Schwarz ^[6]

作者单位： Makerere University Infectious Diseases Institute. ^[1] Antwerp University. ^[2] Makerere University - Johns Hopkins University Research Collaboration. ^[3] Johns Hopkins University. ^[4] Makerere University. ^[5] University of California San Francisco. ^[6]

DOI 10.21203/rs.3.rs-3175598/v1

PMID 37502917

发布时间 2023-10-12

基金项目

D43 TW009343/TW/FIC NIH HHS/United States D43 TW009771/TW/FIC NIH HHS/United States P30 AI027763/AI/NIAID NIH HHS/United States

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Research square

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

检索历史清除

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Research square

相似文献

同项目论文

Research square

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Research square

相似文献

同项目论文

Research square

相关期刊

检索历史清除